Expertise in
45
conditions

Dr. Atul Butala

Hematology
Atul Butala Physician PC
807 Newell St, 
Utica, NY 
Offers Telehealth
Expertise in
45
conditions
Atul Butala Physician PC
807 Newell St, 
Utica, NY 

Overview

Atul Butala is a Hematologist practicing medicine in Utica, New York.

Dr. Butala is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Metastatic Pleural Tumor, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

He is actively involved in clinical research, participating in 12 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NY

Hospital Affiliations

Wynn Hospital
Rome Memorial Hospital, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Atul Butala Physician PC
807 Newell St, Utica, NY 13502
Other Locations
Centrex Clinical Laboratories Inc
201 E State St, Herkimer, NY 13350

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Other, Procedure
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
56
conditions
Dr. Sultana Razia
Hematology
Expertise in
56
conditions
Dr. Sultana Razia
Hematology
Referral may be required

Dr Daniel C. Goodman

1729 Burrstone Rd, 
New Hartford, NY 
 (1.1 miles away)
315-798-1632
Experience:
44+ years
Languages Spoken:
English
See accepted insurances

Sultana Razia is a Hematologist practicing medicine in New Hartford, New York. She has been practicing medicine for over 44 years. Dr. Razia is highly rated in 56 conditions, according to our data. Her clinical expertise encompasses Hemochromatosis, Subacute Combined Degeneration, Endometrial Cancer, Salpingo-Oophorectomy, and Bone Marrow Aspiration.

Expertise in
20
conditions
Dr. Stephen Graziano
Hematology
Expertise in
20
conditions
Dr. Stephen Graziano
Hematology
Referral may be required

Upstate Medical University

750 E Adams St, 
Syracuse, NY 
 (44.7 miles away)
315-464-8200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Graziano is a Hematologist practicing medicine in Syracuse, New York. Dr. Graziano is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Endoscopy.

Expertise in
34
conditions
Dr. Manzurul Sikder
Hematology
Expertise in
34
conditions
Dr. Manzurul Sikder
Hematology
Referral may be required

Dr Daniel C. Goodman

1729 Burrstone Rd, 
New Hartford, NY 
 (1.1 miles away)
315-798-1500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Manzurul Sikder is a Hematologist practicing medicine in New Hartford, New York. Dr. Sikder is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Multiple Carboxylase Deficiency, Vitamin B12 Deficiency Anemia, Folate Deficiency, Subacute Combined Degeneration, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Atul Butala

How do I make an appointment with Dr. Atul Butala?

You can book an appointment with Dr. Atul Butala by calling their office at 315-798-9325. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Atul Butala a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Atul Butala is classified as an Distinguished expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Atul Butala specialize in?

While Dr. Atul Butala is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Metastatic Pleural Tumor, and Lung Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Atul Butala accept my insurance?

Dr. Atul Butala accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 315-798-9325 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Butala's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 31 Advanced Conditions
    View All 123 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile